Grepafloxacin - CAS 119914-60-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Grepafloxacin is a quinoline antibacterial agent used to treat various bacterial infections.
Brife Description:
antibacterial agent
Raxar; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
antibacterial agent
Canonical SMILES:
1.Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.
Gontijo AV1, Brillault J2, Grégoire N2, Lamarche I2, Gobin P3, Couet W4, Marchand S5. Antimicrob Agents Chemother. 2014 Jul;58(7):3942-9. doi: 10.1128/AAC.02818-14. Epub 2014 May 5.
The aim of this study was to evaluate the biopharmaceutical characteristics of three fluoroquinolones (FQs), ciprofloxacin (CIP), moxifloxacin (MXF), and grepafloxacin (GRX), after delivery via a nebulized aerosol to rats. Bronchoalveolar lavages (BAL) were conducted 0.5, 2, 4, and 6 h after FQ intravenous administration and nebulized aerosol delivery to estimate epithelial lining fluid (ELF) drug concentrations. Plasma drug concentrations were also measured, and profiles of drug concentrations versus time after intravenous administration and nebulized aerosol delivery were virtually superimposable, attesting for rapid and complete systemic absorption of FQs. ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.
2.Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
Pranger AD1, Alffenaar JW, Aarnoutse RE. Curr Pharm Des. 2011;17(27):2900-30.
Fluoroquinolones (FQs) are important drugs to treat drug-resistant tuberculosis. In this review we integrated pharmacokinetic properties (PK) and microbiological susceptibility against M. tuberculosis and eventually evaluated the pharmcodynamic (PD) properties, as well as the influence of co-administered agents on these characteristics, for the currently used FQs (ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin) in TB treatment. Future FQs that are being developed may overcome the problems with FQs that are used in daily practice. Therefore PK and pharmacodynamic (PD) properties of novel FQs (clinafloxacin, garenoxacin, lomefloxacin, sitafloxacin, sparfloxacin, trovafloxacin, gemifloxacin, grepafloxacin and DC-159a) were evaluated in TB treatment as well. Integrating both excellent PK and PD properties, moxifloxacin, possibly at a higher dosage, may fulfil a far more important role in the treatment of multi-drug and early-generation FQ resistant TB than proposed in the current WHO guideline.
3.New therapeutic approaches for treatment of tularaemia: a review.
Boisset S1, Caspar Y1, Sutera V1, Maurin M1. Front Cell Infect Microbiol. 2014 Mar 28;4:40. doi: 10.3389/fcimb.2014.00040. eCollection 2014.
Antibiotic treatment of tularaemia is based on a few drugs, including the fluoroquinolones (e.g., ciprofloxacin), the tetracyclines (e.g., doxycycline), and the aminoglycosides (streptomycin and gentamicin). Because no effective and safe vaccine is currently available, tularaemia prophylaxis following proven exposure to F. tularensis also relies on administration of antibiotics. A number of reasons make it necessary to search for new therapeutic alternatives: the potential toxicity of first-line drugs, especially in children and pregnant women; a high rate of treatment relapses and failures, especially for severe and/or suppurated forms of the disease; and the possible use of antibiotic-resistant strains in the context of a biological threat. This review presents novel therapeutic approaches that have been explored in recent years to improve tularaemia patients' management and prognosis. These new strategies have been evaluated in vitro, in axenic media and cell culture systems and/or in animal models.
4.Alteration of pharmacokinetics of grepafloxacin in type 2 diabetic rats.
Watanabe M1, Kobayashi M, Ogura J, Takahashi N, Yamaguchi H, Iseki K. J Pharm Pharm Sci. 2014;17(1):25-33.
PURPOSE: Patients with type 2 diabetes are generally treated with various pharmacological compounds and are exposed to a high risk of drug-drug interactions. However, alterations of pharmacokinetics in a type 2 diabetes model have been obscure. The present study was undertaken to investigate the effects of type 2 diabetes on the pharmacokinetics of the fluoroquinolone grepafloxacin (GPFX) and the expression level of P-glycoprotein (P-gp), one of the drug efflux transporters.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Topoisomerase Products

CAS 1562066-98-1 Banoxantrone D12 dihydrochloride

Banoxantrone D12 dihydrochloride
(CAS: 1562066-98-1)

The deuterium labeled banoxantrone dihydrochloride. Banoxantrone is a potent topoisomerase II inhibitor.

CAS 29767-20-2 Teniposide

(CAS: 29767-20-2)

Teniposide is a chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia (ALL).It is in a class of drugs known as podoph...

CAS 529488-28-6 GENZ-644282

(CAS: 529488-28-6)

Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibi...

CAS 57576-44-0 Aclarubicin

(CAS: 57576-44-0)

Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. It intercalates into DNA and inter...

CAS 57852-57-0 Idarubicin Hydrochloride

Idarubicin Hydrochloride
(CAS: 57852-57-0)

Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells wi...

CP 117227
(CAS: 154531-78-9)

CP 117227, a dibenzocyclohepten derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed in studies of anticancer.

CAS 70476-82-3 Mitoxantrone HCl

Mitoxantrone HCl
(CAS: 70476-82-3)

Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively.

CAS 161967-81-3 Grepafloxacin Hydrochloride

Grepafloxacin Hydrochloride
(CAS: 161967-81-3)

The hydrochloride salt form of Grepafloxacin, a fluoroquinolone derivative, has been found to be a Type II DNA topoisomerase inhibitor and was once studied as a...

Chemical Structure

CAS 119914-60-2 Grepafloxacin

Quick Inquiry

Verification code

Featured Items